Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S34-S40, August 2002

The Hydrolysis of Bimatoprost in Corneal Tissue Generates a Potent Prostanoid FP Receptor Agonist

Cayman Chemical Company, Ann Arbor, MI, USA

Abstract 

Using human and bovine corneal tissue, we investigated the in vitro metabolism of bimatoprost (17-phenyl-18,19,20-trinor-prostaglandin F ethyl amide, Lumigan (Allergan, Inc, Irvine, CA). Enzymatic amidase activity, which converts bimatoprost to the corresponding prostaglandin carboxylic acid, was found to be present in corneal tissue from both species. Using HPLC and mass spectrometry for analyses, conversion of bimatoprost to 17-phenyl-18,19,20-trinor prostaglandin F continued for at least 24 hours after excision of the cornea, with a conversion rate of approximately 25 μg/24 hours. This hydrolysis product is identical to the free acid of latanoprost with the exception of a double, rather than a single, bond at the carbon 13-14 position. Assuming that this conversion also occurs in vivo at a similar rate, this hydrolysis product may account for the reduction of intraocular pressure occurring in patients treated with bimatoprost.

Keywords:  bimatoprost, cornea, FP receptor, glaucoma, hydrolysis, prostaglandin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Cayman Chemical Company provided 100% of the funding for this article. Kirk M. Maxey, MD, is a paid consultant for Pharmacia, the manufacturer of Xalatan. The authors are employees of Cayman Chemical, which makes and sells bimatoprost, latanoprost, unoprostone, and other PGs as research reagents.

PII: S0039-6257(02)00323-5

Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S34-S40, August 2002